Macleods Pharmaceuticals IPO
Macleods Pharma IPO Details
- Open Date TBA
- Close Date TBA
- Lot Size -
- IPO Size -
- IPO Price Range -
- Min Investment -
- Listing Exchange -
- Basis of Allotment TBA
- Refunds TBA
- Credit to Demat Account TBA
- Listing Date TBA
Macleods Pharma IPO Synopsis
Macleods Pharmaceuticals, Mumbai-based drug is set to raise funds worth Rs. 5000 crores and has filed preliminary papers with the Sebi for an initial public offering (IPO).
This will be the second largest pharma IPO to hit the street after Gland Pharma’s Rs 6,480 crore issue in November 2020.
The issue comprises entirely of an offer for sale comprising 60.5 million equity shares by promoters.
Kotak Mahindra Capital Company, Citigroup Global Markets India, Edelweiss Financial Services, ICICI Securities and Nomura Financial Advisory and Securities (India) Private Limited are the book running lead managers to the IPO.
Objective of the Issue
The object of the issue is to:
1. carry out the Offer for Sale of up to 60,482,040 Equity Shares by the selling shareholders
2. enhance the visibility and brand image as well as provide a public market for the equity shares in India
About Macleods Pharmaceuticals
Mumbai-based, Macleods Pharmaceuticals was established in 1989, and is the 7th largest drug firm in Indian Pharmaceutical Market based on domestic sales. The company earns 80% of the domestic sales from non-metros(higher than 70.0% as recorded for the IPM) and 20% from the metros.
The company is engaged in developing, manufacturing, and marketing a wide range of formulations and known for its anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment brand and has a significant presence in North and East India.
Sales from anti-diabetics, cardiovascular, derma, respiratory and hormones therapies grew at a CAGR of 28.5%, 13.4%, 11.7%, 11.0%, and 10.4%, respectively, higher than the IPM growth of 12.3%, 11.1%, 10.8%, 6.2% and 6.9%, for the same therapies in the same periods
The drug firm launched new brands in the last three Fiscals, such as Vildamac and Vildamac M, in the anti-diabetic market, has gained market share among non-innovator brands in the IPM (Vildamac comprised 7.3% of the Vildagliptin market, and Vildamac M comprised a market share of 8.6% of the Vildagliptin+Metformin market) by domestic sales
The company has presence in more than 170 countries across developed and emerging markets in North America, Europe, Africa, Asia, South America etc
Macleods also has an extensive portfolio of anti-TB products, and has the highest number of WHO prequalified anti-TB products globally with 32 registrations.
Macleods Pharmaceuticals Financial Status
Profit and Loss
Balance Sheet
Particulars (in Rs. Crores) | FY21 | FY20 | FY19 |
---|---|---|---|
Revenue | 7199.4 | 6902.8 | 5870.4 |
EBITDA | 2096.7 | 1724.3 | 1340.9 |
PAT | 1630.7 | 1461.2 | 1192.1 |
Particulars (in Rs. Crores) | FY21 | FY20 | FY19 |
---|---|---|---|
Total Assets | 5734.7 | 9573.4 | 7568.9 |
Share Capital | 20.0 | 20.0 | 20.0 |
Total Borrowings | 79.7 | 36.1 | 131.9 |
Particulars (in Rs. Crores) | FY21 | FY20 | FY19 |
---|---|---|---|
Net cash generated from / (used in) operating activities | 1268.46 | 1373.42 | 694.21 |
Net cash from / (used in) investing activities | -1337.59 | -1164.58 | -785.53 |
Net cash flow from / (used in) financing activities | 29.50 | -108.58 | 63.14 |
Net increase (decrease) in cash and cash equivalents | -39.64 | 100.27 | -28.18 |
Peer Comparison
Name of the Company | Total Revenue | Basic EPS | Nav Rs. per share | PE | RoNW% |
---|---|---|---|---|---|
Macleods Pharmaceuticals Limited |
7,199.4 | 33.74 | 63.37 | NA | 53.3% |
Torrent Pharmaceuticals Limited | 8004.8 | 73.98 | 344.94 | 35.11 | 21.5% |
Alkem Laboratories Limited | 8865.0 | 132.57 | 632.13 | 26.41 | 21.4% |
Sun Pharmaceutical Industries Limited |
33498.1 | 12.1 | 206.22 | 73.91 | 4.6% |
Dr. Reddy's Laboratories Limited | 19047.5 | 117.67 | 1,064.51 | 37.25 | 11.1% |
Lupin Limited | 15163.0 | 26.84 | 305.46 | 30.18 | 8.9% |
Cadila Healthcare Limited | 15102.2 | 20.84 | 145.83 | 19.26 | 14.64% |
Eris Lifesciences Limited | 1211.9 | 26.16 | 116.1 | 26.76 | 22.53% |
Ipca Laboratories Limited | 5420.0 | 90.11 | 371.79 | 11.14 | 24.20% |
The key points are-
Macleods Pharma IPO Key Points
-
Strengths
1. One of the Leading and Fast-Growing Companies with Significant Presence in the IPM
2. Proven Track Record of Building Brands
3. Diversified Presence across Global Markets with Calibrated Business Model
4. R&D-Led Differentiated Portfolio of Products
5. Diversified and quality-compliant manufacturing capabilities -
Risks
1. It may experience a shortfall in the supply of the raw materials or an increase in their prices, or of other input costs.
2. It could experience a material slowdown or shutdown in the manufacturing or R&D operations
3. Failure to meet various quality standards and good manufacturing practices may result in increased product liabilities
4. It derives a significant portion of its revenue from operations from a limited number of markets
How to apply for IPO?
-
Login to your 5paisa account and select the issue in the
current IPO section -
Enter the number of lots and price at which you wish to
apply for -
Enter your UPI ID and click on submit. With this, your
bid will be placed with the exchange -
You will receive a mandate notification to block funds in
your UPI app -
Approve the mandate request on your UPI and funds
will be blocked
Open account in 5 minutes
Be a part of the 5paisa community now with 10 million mobile app users
Macleods Pharma IPO FAQs
What is the minimum lot size and investment required for the Macleods Pharmaceuticals IPO?
Macleods Pharmaceuticals IPO details are yet to be announced.
What is the price band of the IPO?
Macleods Pharmaceuticals IPO details are yet to be announced.
When does the Macleods Pharmaceuticals issue open and close?
Macleods Pharmaceuticals IPO details are yet to be announced.
What is the size of Macleods Pharmaceuticals IPO issue?
The IPO comprises entirely of an offer for sale comprising 60.5 million equity shares by promoters.
Who are the promoters/key personnels of Macleods Pharmaceuticals?
Macleods Pharmaceuticals is promoted by Girdharilal Bawri, Banwarilal Bawri and Dr. Rajendra Agarwal
What is the allotment date of Macleods Pharmaceuticals?
Macleods Pharmaceuticals IPO details are yet to be announced.
What is the Macleods Pharmaceuticals listing date?
Macleods Pharmaceuticals IPO details are yet to be announced.
Who are the book runners for Macleods Pharmaceuticals IPO?
Kotak Mahindra Capital Company, Citigroup Global Markets India, Edelweiss Financial Services, ICICI Securities and Nomura Financial Advisory and Securities (India) Private Limited are the book running lead managers to the issue.
What is the objective of the issue?
The proceeds from the issue will be used for:
1. carry out the Offer for Sale of up to 60,482,040 Equity Shares by the selling shareholders
2. enhance the visibility and brand image as well as provide a public market for the equity shares in India.
How to apply for the Macleods Pharmaceuticals IPO?
To apply for the IPO, follow the steps given below
1. Login to your 5paisa account and select the issue in the current IPO section
2. Enter the number of lots and price at which you wish to apply for
3. Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange
4. You will receive a mandate notification to block funds in your UPI app
IPO News
Ramdevbaba Solvent IPO Subscribed 126.21 times
About the Ramdevbaba Solvent IPO Ramdevbaba Solvent IPO has a face value of ₹10 per share and ...
IPO Blog
Ramdevbaba Solvent IPO Allotment Status
Quick take on the IPO of Ramdevbaba Solvent Ltd The stock of Ramdevbaba Solvent Ltd has a face value of ₹10 per share and it is a book built issue. The price for the book building issue is set in the price band of ₹80 to ₹85 per share. Being a book built issue, the final price of the IPO will be discovered in this price band. The Ramdevbaba ...
IPO Guide
IPO Cycle
The IPO cycle, also referred to as Initial Public Offering Cycle, allows private companies to go public and offer the company's shares to the general public for the first time. It ...